ALT: Rega marang bathi kanthi panyesuaian wutah altimmune.com

The historical PEG ratio reflects the impact of partnership expectations for the final tests of the obesity drug. Altimmune, Inc. (ALT) develops advanced peptide therapies to combat metabolic disorders, leveraging US laboratories and inhalation technologies. The value of 0.00 serves as a current metric that allows for the comparison of the company's market value with its earnings growth rate.

ALT - Pangali PEG Altimmune ing rentang 04.07.2022 - 10.11.2026

Rincian metrik lan analitis perusahaan Altimmune, Inc. (ALT)

- rega pasar lan target rega analis:

Kutipan saham Altimmune Inc|ALT - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Nilai pasar Altimmune Corp|ALT - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data nilai buku modal saham:

Rega Buku Saham Altimmune|ALT - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku altimmune.com|ALT - Total Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

- statistik bathi lan rasio pasar:

ALT - Bathi resik perusahaan|Bathi mangsa ngarep Altimmune, Inc.|ALT - Pangali P/E|Pangali Forward P/E Altimmune Pharma|ALT - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Altimmune Corp|ALT - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone patang kuartal pungkasan Altimmune|ALT - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan altimmune.com|ALT - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Altimmune, Inc.

Analisis fundamental perusahaan:Altimmune Inc ALT

This metric correlates market capitalization with earnings growth rates, allowing for the identification of an undervalued asset when the value falls below one. By analyzing the average peg_co level, an investor assesses the growth potential of Altimmune, Inc. (ALT) as its anti-obesity drug prepares for large-scale testing and the company seeks a strategic pharmaceutical partner to execute late-stage research.

Perusahaan pesaing